PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Drug Interaction Study Between Raltegravir And UK-453,061
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00784420
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: PF-00299804
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00783328
- Locations
- 🇯🇵
Pfizer Investigational Site, Sunto-gun, Shizuoka, Japan
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDrug: PF-00610355
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00783406
- Locations
- 🇩🇪
Pfizer Investigational Site, Wiesbaden, Germany
Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: suspension IRDrug: CR 1Drug: CR 2Drug: CR 3
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00782600
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00783484
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Cumulative Irritation Test
Phase 1
Completed
- Conditions
- Tinea Pedis
- Interventions
- Drug: AN2718Other: Sodium Lauryl Sulfate
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT00781664
- Locations
- 🇺🇸
The Education and Research Foundation, Inc., Lynchburg, Virginia, United States
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Terminated
- Conditions
- Breast Neoplasms
- Interventions
- Other: Aromasin
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT00776659
- Locations
- 🇮🇳
Pfizer Investigational Site, Lucknow, Uttar Pradesh, India
Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.
Completed
- Conditions
- Blood Coagulation
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 553
- Registration Number
- NCT00775398
A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin
Phase 1
Completed
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00774605
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating Changes In Mammographic Breast Density
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 507
- Registration Number
- NCT00774267
- Locations
- 🇳🇴
Pfizer Investigational Site, Hamar, Norway
© Copyright 2025. All Rights Reserved by MedPath